A Multicenter, Observational Study to Describe the Effectiveness and Treatment Patterns of Dacomitinib Among Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Patients With Brain Metastasis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dacomitinib (Primary)
Indications Brain metastases; Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

07 Feb 2025 Planned initiation date changed from 1 Sep 2024 to 30 Sep 2024.
07 Feb 2025 Status changed from not yet recruiting to withdrawn prior to enrolment.
07 May 2024 Planned initiation date changed from 15 Jan 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight